Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide consisting of nine amino acids. It was first discovered in 1977 by Schoenenberger and Monnier, who isolated it from the cerebral venous blood of rabbits during slow-wave sleep. The peptide was named for its ability to induce delta-wave sleep patterns when administered intravenously to recipient animals. Its significance lies in its role as one of the first identified endogenous sleep-promoting substances, providing a direct biochemical link between peptide signaling and sleep regulation. While initially characterized for its soporific effects, subsequent research has revealed a broader physiological role, including potential interactions with stress response systems, circadian rhythms, and neuroprotection. Despite its discovery decades ago, its precise physiological role and receptor mechanisms remain areas of active investigation.
Quick Facts
| Also Known As | DSIP, Delta Sleep-Inducing Peptide (human), Delta Sleep-Inducing Peptide (porcine) |
|---|---|
| Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| Molecular Formula | C35H48N10O15 |
| Molecular Weight | 848.8 Da |
| PubChem CID | 68816 |
Research Parameters
| Half-Life | Unknown in humans. In rodent models, plasma half-life is very short, estimated in the range of several minutes. |
|---|---|
| Stability | Lyophilized powder is stable for at least 24 months when stored at -20°C, protected from light and moisture. After reconstitution in a sterile, slightly acidic buffer (e.g., acetic acid solution) or bacteriostatic water, it should be stored at 2-8°C and used promptly, typically within a few days to a week, as specific stability data for reconstituted solutions are limited. |
| Solubility | Recommended reconstitution in sterile bacteriostatic water or 0.9% sodium chloride (saline). For enhanced solubility and stability, a dilute acetic acid solution (e.g., 0.1% acetic acid) is often used in research settings. |
| Vial Size | 2 mg |
| Storage (Lyophilized) | -20°C or below, in a desiccated environment, protected from light. |
| Storage (Reconstituted) | 2-8°C (refrigerated) for short-term storage. For longer-term storage, aliquoting and freezing at -20°C or -80°C is recommended, though freeze-thaw cycles should be minimized. |
| Typical Research Dose | Not established for human research. Animal research doses range from approximately 1 to 50 mcg/kg. |
| Cycle Parameters | No standardized human research cycle exists. Preclinical animal protocols vary widely, from single acute injections to daily administration for periods of 1-4 weeks. |
| Amino Acid Count | 9 |
Mechanism of Action
The exact mechanism of action for DSIP is not fully elucidated, and it is believed to act through multiple, potentially indirect pathways rather than a single high-affinity receptor. Its effects are thought to be mediated through modulation of neurotransmitter systems and neuroendocrine axes.
Modulation of Neurotransmitter Systems: DSIP may influence the balance of monoaminergic neurotransmitters (e.g., serotonin, norepinephrine) and amino acid neurotransmitters (e.g., GABA), which are critically involved in sleep-wake regulation and arousal states.
Interaction with Neuroendocrine Axes: Research suggests DSIP can modulate the activity of the hypothalamic-pituitary-adrenal (HPA) axis, potentially reducing the secretion of stress hormones like corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH), which may contribute to its sleep-promoting and anti-stress effects.
Possible Opioid System Involvement: Some studies indicate DSIP might interact with endogenous opioid systems, as its effects can be partially blocked by opioid antagonists like naloxone, suggesting a non-classical opioid receptor pathway.
Cellular Signaling and Gene Expression: In vitro studies suggest DSIP may influence second messenger systems and gene expression related to cellular stress responses and adaptive functions, though these pathways are not yet well-defined in vivo.
Research Applications
Sleep and Circadian Rhythm Research: DSIP is a classic tool for investigating the neurochemical basis of sleep, particularly slow-wave (delta) sleep. Studies explore its potential to normalize sleep architecture in models of sleep disturbance and its interaction with circadian clock genes.
Stress and Anxiety Research: Due to its apparent ability to modulate the HPA axis, DSIP is studied in models of acute and chronic stress. Research investigates its potential anxiolytic-like effects and its role in promoting physiological adaptation to stressors.
Neuroprotection and Addiction Research: Preliminary animal studies have explored DSIP's potential protective effects against neuronal damage induced by toxins or ischemia. Other lines of inquiry have examined its influence on withdrawal symptoms in models of alcohol and opioid dependence, possibly linked to its modulation of stress and neurotransmitter systems.
Safety & Side Effects
A comprehensive safety profile from controlled human studies does not exist. In animal studies, DSIP administered at research doses generally appears well-tolerated without severe acute toxicity. Anecdotal reports from unofficial human use mention transient drowsiness, lethargy, or headache. Theoretical concerns include the potential for dysregulation of natural sleep architecture with chronic, unguided use and unknown immunogenicity due to its peptide nature. Its effects on developing fetuses or individuals with specific neurological conditions are completely unknown.
Dosage Information
This information is derived solely from preclinical animal research and is not for human use. Typical research doses in animal models (e.g., rats, rabbits) range from 1 to 50 nmol/kg (approximately 0.85 to 42.5 mcg/kg), often administered via intravenous (IV) or intracerebroventricular (ICV) injection to study central effects. Subcutaneous (SC) and intraperitoneal (IP) routes have also been used. Dosing frequency in studies is typically acute (single administration) to observe immediate effects on sleep or stress hormones, though some chronic administration protocols exist. Duration of administration in chronic studies varies from several days to a few weeks.
References
Monnier, M., & Schoenenberger, G.A. (1977). Characterization, sequence, and synthesis of the sleep peptide delta-sleep-inducing peptide (DSIP). Experientia, 33(4), 548-552.
Graf, M.V., & Kastin, A.J. (1984). Delta-sleep-inducing peptide (DSIP): a review. Neuroscience & Biobehavioral Reviews, 8(1), 83-93.
Kovalzon, V.M., & Strekalova, T.V. (2006). Delta-sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry, 97(2), 303-309.
Schneider-Helmert, D., & Schoenenberger, G.A. (1983). Effects of DSIP in man. Neuropsychobiology, 9(4), 197-206.
Yehuda, S., & Mostofsky, D.I. (1993). Delta sleep-inducing peptide (DSIP) and its analogs: a review. Peptides, 14(4), 785-791.
Inoue, S., et al. (1984). Differential effects of delta-sleep-inducing peptide (DSIP) and its analog on sleep and brain temperature in rats. Life Sciences, 35(18), 1885-1891.